Neuroblastoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 35 expanded access programs, clinical trials, and compassionate use pathways listed for Neuroblastoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with neuroblastoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 9 programs are currently active or recruiting, with the remaining 26 in other lifecycle stages. Sponsors actively running programs in this area include Memorial Sloan Kettering Cancer Center, Children's Oncology Group, Giselle Sholler, Jubilant DraxImage Inc., New Approaches to Neuroblastoma Therapy Consortium, and others.
By recruiting status
Snapshot of where every Neuroblastoma program currently sits in its lifecycle.
- Active / Recruiting9
- Inactive26
Top sponsors
Organisations running the most Neuroblastoma programs in the directory.
- Memorial Sloan Kettering Cancer Center5 programs
- Children's Oncology Group4 programs
- Giselle Sholler4 programs
- Jubilant DraxImage Inc.2 programs
- New Approaches to Neuroblastoma Therapy Consortium2 programs
- Adaptimmune1 program
- Baylor College of Medicine1 program
- Children's Hospital Los Angeles1 program
- Children's Hospital Medical Center, Cincinnati1 program
- Clarity Pharmaceuticals Ltd1 program
Neuroblastoma programs (35)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 67Cu-SARTATE™ Therapy for Children with High-Risk, Relapsed, or Hard-to-Treat Neuroblastoma — Clarity Pharmaceuticals Ltd
- Study on Tumor Cell Vaccine and Low-Dose Chemotherapy for High-Risk Neuroblastoma in Children — Baylor College of Medicine
- Study on Alpha/Beta T and B Cell Depletion with Zoledronic Acid for Treating Solid Tumors — University of Florida
- Study on Using Donor Memory-Like Natural Killer Cells for Treating Relapsed or Hard-to-Treat Neuroblastoma — Children's Hospital Medical Center, Cincinnati
- Phase II STING Trial: Testing a New Treatment for High-Risk Neuroblastoma — New Approaches to Neuroblastoma Therapy Consortium
- Study on Response and Biology-Based Risk Factor-Guided Therapy for Young Patients with Non-High Risk Neuroblastoma — Children's Oncology Group
- Study on Palbociclib with Chemotherapy for Children and Young Adults with Hard-to-Treat Solid Tumors — Pfizer
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma — Children's Oncology Group
- Study on Dinutuximab, GM-CSF, Isotretinoin with Irinotecan and Temozolomide for High-Risk Neuroblastoma After Intensive Therapy — Children's Oncology Group
- 131-I-MIBG Therapy for Hard-to-Treat Neuroblastoma: Expanded Access Program — John Maris
- 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol — Kieuhoa Vo
- Compassionate Use of 131I-MIBG Therapy for Patients with Hard-to-Treat Neuroblastoma and Metastatic Pheochromocytoma — Northwell Health
- Study on a Vaccine Combined with Beta-glucan for People with Neuroblastoma — Memorial Sloan Kettering Cancer Center
- A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma — Memorial Sloan Kettering Cancer Center
- Study on Cabozantinib to Prevent Progression or Return of High-Risk Pediatric Solid Tumors — Nationwide Children's Hospital
- Study on Iobenguane (131-I) and Vorinostat for Treating Recurrent or Progressive High-Risk Neuroblastoma — Jubilant DraxImage Inc.
- An Intermediate Expanded Use Trial of DFMO — Giselle Sholler
- Study on Bivalent Vaccine with OPT-821 and Oral β-glucan for High-Risk Neuroblastoma — Memorial Sloan Kettering Cancer Center
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma — National Cancer Institute (NCI)
- Study on Eflornithine (DFMO) and Etoposide for Neuroblastoma That Has Returned or Not Responded to Treatment — Giselle Sholler
- Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma — GE Healthcare
- Expanded Access Protocol Using 131I-MIBG — Jubilant DraxImage Inc.
- Study on Iodine I 131 Metaiodobenzylguanidine for Treating Recurrent or Resistant Neuroblastoma, Malignant Pheochromocytoma, or Paraganglioma — Memorial Sloan Kettering Cancer Center
- Study on Methionine PET/CT Imaging for Cancer Patients — St. Jude Children's Research Hospital
- Study on Intensive Chemotherapy and Stem Cell Rescue for Patients with High-Risk Neuroblastoma — Masonic Cancer Center, University of Minnesota
- Study on Reduced Chemotherapy and Monoclonal Antibody Therapy for Children with Neuroblastoma — Memorial Sloan Kettering Cancer Center
- Study on MIBG Treatment with Vorinostat and Dinutuximab for Neuroblastoma — New Approaches to Neuroblastoma Therapy Consortium
- Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow — Y-mAbs Therapeutics
- Neuroblastoma Maintenance Therapy Trial — Giselle Sholler
- Study on Personalized Treatment for Children with Advanced Neuroblastoma — Giselle Sholler
- Rapid Infusion Study for Dinutuximab in Children with High-Risk Neuroblastoma — Children's Hospital Los Angeles
- SPEARHEAD-3 Study for Children and Young Adults — Adaptimmune
- Study on the Safety and Effectiveness of Ribociclib with Topotecan and Temozolomide in Children with Relapsed or Hard-to-Treat Neuroblastoma and Other Solid Tumors — Novartis Pharmaceuticals
- Study on Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors — Merck Sharp & Dohme LLC
- Tegavivint for Treating Recurrent or Hard-to-Treat Solid Tumors, Including Lymphomas and Desmoid Tumors — Children's Oncology Group
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Neuroblastoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.